Short-Course Meropenem for ICU Pulmonary Infiltrates

Phase 3, randomised, open-label trial of meropenem in bacterial infection and pneumonia (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Combined measure of either emergence of antimicrobial resistance or isolation of a potential pathogen detected in any positive clinical cultures that are deemed a clinically significant infection. Started Oct 2006; status: terminated.